A Phase 1 interventional study of BMS-986463 in High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC) and Non-small Cell Lung Cancer (NSCLC), sponsored by Bristol-Myers Squibb. Recruiting at 17 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,632 are open to participants now.
This study's planned enrollment of 240 is above the median of 62 across 5,213 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Drug: BMS-986463
Drug: BMS-986463
Specified dose on specified days
Number of participants with adverse events (AEs)
Time frame: Up to 108 weeks
Number of participants with serious adverse events (SAEs)
Time frame: Up to 108 weeks
Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) criteria
Time frame: Up to 108 weeks
Number of participants with AEs leading to discontinuation
Time frame: Up to 108 weeks
Number of participants with AEs leading to death
Time frame: Up to 108 weeks
Maximum observed concentration (Cmax)
Time frame: Up to 104 weeks
Area under the concentration-time curve (AUC)
Time frame: Up to 104 weeks
Time of maximum observed concentration (Tmax)
Time frame: Up to 104 weeks
Objective response rate (ORR)
Time frame: Up to 104 weeks
Disease control rate (DCR)
Time frame: Up to 104 weeks
Duration of response (DOR)
Time frame: Up to 104 weeks
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Sap, Csr
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung→
Bristol-Myers Squibb